...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
AGORACOM NEWS FLASH

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Sincerely,

George et al

Message: Re: Zenith trial partners
5
Jan 29, 2023 02:49PM
1
Jan 30, 2023 10:16AM

Jan 30, 2023 11:58AM
2
Jan 30, 2023 03:07PM
3
Jan 30, 2023 03:27PM
3
Jan 30, 2023 06:05PM
2
Jan 30, 2023 07:22PM
3
Jan 31, 2023 06:44AM
2
Jan 31, 2023 10:27AM
1
Feb 01, 2023 01:13PM
5
Feb 01, 2023 06:42PM
2
Feb 01, 2023 08:07PM
3
Feb 01, 2023 09:11PM
2
Feb 01, 2023 11:14PM
5
Feb 02, 2023 02:15AM

I agree, RVXoldtimer.  Zenith shareholders hold an RPS interest in RVX's success so it would be in their interest to not let RVX fail in commercializing apabetalone, so I don't see the conflict of interest in Zenith loaning to or investing in RVX.  Zenith chairman recently exclamated that the RVX Royalty Preferred Shares were worth an enormous amount to Zenith.

So there you have it, right from the horse's mouth.

Geez KBC, could you not save us all from the obvious banter, and just pay the Ask...  

No one here is hanging on your every insinuation for direction on 'buy or sell'.  

JMHO

2
Feb 02, 2023 12:31PM
2
Feb 02, 2023 02:00PM
3
Feb 02, 2023 03:16PM
2
Feb 02, 2023 03:59PM
2
Feb 02, 2023 04:24PM
1
Feb 02, 2023 06:54PM
2
Feb 04, 2023 06:40PM
Share
New Message
Please login to post a reply